Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760955 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy
A Phase 2 study of Diabetic Neuropathies, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT00760955: Completed Phase 2 study of Diabetic Neuropathies, sponsored by Takeda.
NCT00760955 is a Phase 2 study of Diabetic Neuropathies that has completed, run by Takeda. The registered enrollment target is 338 participants, above the 286-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00760955, a Phase 2 study of Diabetic Neuropathies, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAK-583
Study Locations (20)
Florida
- - Largo
- - Miami
- - New Port Richey
- - Palm Beach Gardens
- - Sunrise
- - West Palm Beach
California
- - Huntington Beach
- - La Jolla
- - Los Angeles
- - Pasadena
- - Tustin
Arizona
- - Mesa
- - Peoria
- - Phoenix
- - Tucson
Arkansas
- - Jonesboro
Georgia
- - Decatur
Idaho
- - Idaho Falls
Illinois
- - Chicago
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00760955 record still lists
NCT00760955 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, above the 286-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (18% higher).
The record links to 1 condition, with Diabetic Neuropathies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00760955 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00760955 about?
NCT00760955 is a clinical study titled "Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy". The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.
What is the current status of trial NCT00760955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2006-09. Estimated completion is 2008-02.
What conditions does trial NCT00760955 study?
This clinical trial studies the following conditions: Diabetic Neuropathies.
What interventions are being tested in trial NCT00760955?
The interventions under investigation include: Placebo (DRUG), TAK-583 (DRUG).
Who is sponsoring clinical trial NCT00760955?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00760955 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00760955's enrollment target sits among peer trials
338 4th of 8 higher than 5 of 8 other Diabetic Neuropathies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Neuropathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
COMPLETED · Phase 2
-
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
COMPLETED · Phase 2
-
Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy
RECRUITING · Phase 1
-
Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain
ACTIVE NOT RECRUITING · NA
-
Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)
COMPLETED
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia